⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights

Company

CRO Partners
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

STM-434 (stm-434) | Accelerate Your Fibrosis Research

Home/Drugs/STM-434

STM-434

stm-434

Phase 2a

Sponsor: Acceleron Pharma

Indication: IPF

Mechanism of Action

Activin receptor ligand trap

Target: Activin

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT02262455

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Phase:PHASE1Org:Santa Maria Biotherapeutics

View all trials on ClinicalTrials.gov

Relevant Publications (PubMed)

No recent publications found for stm-434.

Validated Models

This drug has been validated in the following preclinical models: